Relief Therapeutics Holding AG (RLF) - Total Liabilities
Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has total liabilities worth CHF15.35 Million CHF (≈ $19.41 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RLF cash generation efficiency to assess how effectively this company generates cash.
Relief Therapeutics Holding AG - Total Liabilities Trend (2006–2024)
This chart illustrates how Relief Therapeutics Holding AG's total liabilities have evolved over time, based on quarterly financial data. Check Relief Therapeutics Holding AG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Relief Therapeutics Holding AG Competitors by Total Liabilities
The table below lists competitors of Relief Therapeutics Holding AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vext Science Inc
F:VV5
|
Germany | €61.84 Million |
|
Intercure
TA:INCR
|
Israel | ILA319.52 Million |
|
Midland Exploration Inc
V:MD
|
Canada | CA$2.11 Million |
|
Eurospan Holdings Bhd
KLSE:7094
|
Malaysia | RM6.99 Million |
|
Dacome International Ltd
TWO:9960
|
Taiwan | NT$418.29 Million |
|
Urbanise.com Ltd
AU:UBN
|
Australia | AU$12.05 Million |
|
Milux Corporation Bhd
KLSE:7935
|
Malaysia | RM30.37 Million |
|
Biohit Oyj B
HE:BIOBV
|
Finland | €4.90 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Relief Therapeutics Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Relief Therapeutics Holding AG worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relief Therapeutics Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relief Therapeutics Holding AG (2006–2024)
The table below shows the annual total liabilities of Relief Therapeutics Holding AG from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF16.56 Million ≈ $20.94 Million |
-31.46% |
| 2023-12-31 | CHF24.16 Million ≈ $30.55 Million |
-44.30% |
| 2022-12-31 | CHF43.38 Million ≈ $54.85 Million |
-38.10% |
| 2021-12-31 | CHF70.09 Million ≈ $88.61 Million |
+537.05% |
| 2020-12-31 | CHF11.00 Million ≈ $13.91 Million |
+97.70% |
| 2019-12-31 | CHF5.57 Million ≈ $7.04 Million |
-61.06% |
| 2018-12-31 | CHF14.29 Million ≈ $18.07 Million |
+42.56% |
| 2017-12-31 | CHF10.03 Million ≈ $12.68 Million |
+9.13% |
| 2016-12-31 | CHF9.19 Million ≈ $11.61 Million |
-26.36% |
| 2015-12-31 | CHF12.48 Million ≈ $15.77 Million |
-18.31% |
| 2014-12-31 | CHF15.27 Million ≈ $19.31 Million |
-39.79% |
| 2013-12-31 | CHF25.37 Million ≈ $32.07 Million |
+538.33% |
| 2012-12-31 | CHF3.97 Million ≈ $5.02 Million |
+41.26% |
| 2011-12-31 | CHF2.81 Million ≈ $3.56 Million |
-52.54% |
| 2010-12-31 | CHF5.93 Million ≈ $7.49 Million |
-30.15% |
| 2009-12-31 | CHF8.49 Million ≈ $10.73 Million |
+9.84% |
| 2008-12-31 | CHF7.73 Million ≈ $9.77 Million |
-47.21% |
| 2007-12-31 | CHF14.63 Million ≈ $18.50 Million |
+37.67% |
| 2006-12-31 | CHF10.63 Million ≈ $13.44 Million |
-- |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more